TUSC2 Immunotherapy Combined With PD-1 Blockade for Stronger Tumor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer therapies targeting tumor suppressor genes like TUSC2 lack efficacy enhancement strategies, particularly when combined with immune checkpoint inhibitors.
Innovation Solution
Administering TUSC2 therapy in conjunction with immune checkpoint inhibitors, such as anti-PD1 antibodies, to enhance tumor suppressor activity and immune cell function, including the use of TUSC2 polypeptides or expression vectors delivered via nanoparticles or viral vectors, along with additional agents like anti-inflammatory drugs and protein kinase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TUSC2 therapy is administered alone, then tumor suppressor activity is restored, but anti-tumor efficacy is insufficient
Solution Approach 1:
The patent combines TUSC2 therapy with immune checkpoint inhibitors (such as anti-PD1 antibodies) to create a synergistic treatment approach. This merging of two different therapeutic mechanisms - tumor suppressor restoration and immune system activation - produces enhanced anti-tumor efficacy that exceeds the sum of individual treatments, directly resolving the contradiction between restoring tumor suppressor activity and achieving sufficient anti-tumor efficacy
2Productivity
If immune checkpoint inhibitors are administered alone, then immune cell function is enhanced, but tumor suppressor restoration is not achieved
Solution Approach 1:
The patent merges immune checkpoint inhibition with TUSC2-mediated tumor suppressor restoration. This combination ensures that both immune cell function enhancement and tumor suppressor restoration are achieved simultaneously, resolving the contradiction where one treatment enhances immune function but fails to restore tumor suppressor activity
3Productivity
If combination therapy is used, then anti-tumor efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs preliminary action by first restoring tumor suppressor genes (such as TUSC2) before or concurrent with immune checkpoint inhibition. This sequencing creates a more favorable tumor microenvironment that enhances subsequent immune therapy effectiveness, thereby achieving enhanced anti-tumor efficacy while managing treatment complexity through strategic timing rather than simultaneous complex administration
Data Source
Figure 1A~1D
Figure 1E
Figure 2A
AI summary
A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.